Neuroprotective effect of neuropeptide Y against beta-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production

Neurodegenerative Diseases

Volumn 8, Issue 5, 2011, Pages 300-309

  Croce, Nicoletta ^a   Dinallo, Vincenzo ^a   Ricci, Valerio ^a   Federici, Giorgio ^a   Caltagirone, Carlo ^a   Bernardini, Sergio ^a   Angelucci, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Beta amyloid; Neuroblastoma; Neuropeptide Y; Neurotrophins

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; NEUROTROPHIN;

ARTICLE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA ISOLATION;

AMYLOID BETA-PEPTIDES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEUROBLASTOMA; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS;

EID: 79958785450     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000323468     Document Type: Article

References (64)

1. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006;368:387-403. (Pubitemid 44108123)
2. Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease - Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann NY Acad Sci 2000;924:17-25.
3. Colton CA, Vitek MP: NPY and chronic neurodegenerative disease: NPY family of peptides in neurobiology, cardiovascular and metabolic disorders from genes to therapeutics. J Neural Transm 2006;113:231-238.
4. Gutman AR, Yang Y, Ressler KJ, Davis M: The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J Neurosci 2008;28:12682-12690.
5. El Bahh B, Balosso S, Hamilton T, Herzog H, Beck-Sickinger AG, Sperk G, Gehlert DR, Vezzani A, Colmers WF: The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur J Neurosci 2005;22:1417-1430. (Pubitemid 41442414)
6. Goyal SN, Upadhya MA, Kokare DM, Bhisikar SM, Subhedar NK: Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: involvement of NPY Y1 receptors. Brain Res 2009;1266:45-53.
7. Martel JC, Alagar R, Robitaille Y, Quirion R: Neuropeptide Y receptor binding sites in human brain: possible alteration in Alzheimer's disease. Brain Res 1990;519:228-235. (Pubitemid 20199692)
8. Koide S, Onishi H, Hashimoto H, Kai T, Yamagami S: Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci Lett 1995;198:149-151.
9. Alom J, Galard R, Catalan R, Castellanos JM, Schwartz S, Tolosa E: Cerebrospinal fluid neuropeptide Y in Alzheimer's disease. Eur Neurol 1990;30:207-210. (Pubitemid 20229752)
10. Rose JB, Crews L, Rockenstein E, Adame A, Mante M, Hersh LB, Gage FH, Spencer B, Potkar R, Marr RA, Masliah E: Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J Neurosci 2009;29:1115-1125.
11. Silva AP, Pinheiro PS, Carvalho AP, Carvalho CM, Jakobsen B, Zimmer J, Malva JO: Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J 2003;17:1118-1120.
12. Decressac M, Wright B, David B, Tyers P, Jaber M, Barker RA, Gaillard A: Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus 2010, Epub ahead of print.
13. Howell OW, Silva S, Scharfman HE, Sosunov AA, Zaben M, Shatya A, McKhann G 2nd, Herzog H, Laskowski A, Gray WP: Neuropeptide Y is important for basal and seizureinduced precursor cell proliferation in the hippocampus. Neurobiol Dis 2007;26:174-188. (Pubitemid 46442789)
14. Howell OW, Doyle K, Goodman JH, Scharfman HE, Herzog H, Pringle A, Beck-Sickinger AG, Gray WP: Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem 2005;93:560-570. (Pubitemid 40617616)
15. Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med 2010;362:329-344.
16. Huang EJ, Richardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736. (Pubitemid 32695243)
17. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF: Cholinergic involvement in Alzheimer's disease: a link with NGF maturation and degradation. J Mol Neurosci 2010;40:230-235.
18. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH: Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009;15:331-337.
19. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC: Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001;98:10439-10444. (Pubitemid 32803038)
20. Tuszynski MH: Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:179-189.
21. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M: Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 1997;49:71-81. (Pubitemid 27453116)
22. Peng S, Wuu J, Mufson EJ, Fahnestock M: Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the preclinical stages of Alzheimer's disease. J Neurochem 2005;93:1412-1421. (Pubitemid 40853264)
23. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Bossù P: Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 2010;7:15-20.
24. Yoshimura R, Ito K, Endo Y: Differentiation/maturation of neuropeptide Y neurons in the corpus callosum is promoted by brain-derived neurotrophic factor in mouse brain slice cultures. Neurosci Lett 2009;450:262-265.
25. Medina-Ortiz WE, García-Arrarás JE: Differential regulation of NPY mRNA expression in embryonic sympathetic and chromaffin cultures by NGF. Brain Res Dev Brain Res 2000;119:155-158. (Pubitemid 30058391)
26. Påhlman S, Hoehner JC, Nånberg E, Hedborg F, Fagerström S, Gestblom C, Johansson I, Larsson U, Lavenius E, Ortoft E, Soderholm H: Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 1995;31A:453-458.
27. Påhlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T: Retinotic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbol ester-induced differentiation. Cell Differ 1984;14:135-144. (Pubitemid 14089031)
28. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, Chang RC: Effects of all-transretinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 2009;30:127-135.
29. Hansel DE, Eipper BA, Ronnett GV: Neuropeptide Y functions as a neuroproliferative factor. Nature 2001;410:940-944. (Pubitemid 32335840)
30. Zukowska-Grojec Z, Pruszczyk P, Colton C, Yao J, Shen GH, Myers AK, Wahlestedt C: Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 1993;14:263-268.
31. Protas L, Qu J, Robinson RB: Neuropeptide Y: neurotransmitter or trophic factor in the heart? News Physiol Sci 2003;18:181-185.
32. Zhao S, Fernald RD: Comprehensive algorhythm for quantitative real-time polymerase chain reaction. J Comput Biol 2005;12:1045-1062.
33. Millucci L, Ghezzi L, Bernardini G, Santucci A: Conformations and biological activities of amyloid β peptide 25-35. Curr Protein Pept Sci 2010;11:54-67.
34. Stanley BG, Leibowitz SF: Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci 1984;35:2635-2642. (Pubitemid 15221101)
35. Flood JF, Hernandez EN, Morley JE: Modulation of memory processing by neuropeptide Y. Brain Res 1987;421:280-290. (Pubitemid 18021635)
36. Redrobe JP, Dumont Y, St-Pierre JA, Quirion R: Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res 1999;848:153-166. (Pubitemid 30001664)
37. Vezzani A, Sperk G: Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides 2004;38:245-252.
38. Bastianetto S, Ramassamy C, DoréS, Christen Y, Poirier J, Quirion R: The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid,. Eur J Neurosci 2000;12:1882-1890. (Pubitemid 30348827)
39. DoréS, Kar S, Quirion R: Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity, Proc Natl Acad Sci USA 1997;94:4772-4777.
40. Del Mar Martinez-Senac M, Villalain J, Gomez-Fernandez JC: Structure of the Alzheimer β-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur J Biochem 1999;265: 744-753. (Pubitemid 29489007)
41. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS: The toxicity in vitro of β-amyloid protein. Biochem J 1995;311:1-16.
42. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW: Structure-activity analyses of β-amyloid peptides: contributions of the β 25-35 region to aggregation and neurotoxicity. J Neurochem 1995;64:253-265.
43. Shearman MS, Ragan CI, Iversen LL: Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc Natl Acad Sci USA 1994;91:1470-1474. (Pubitemid 24059034)
44. Terzi E, Holzemann G, Seelig J: Reversible random coil-β-sheet transition of the Alzheimer β-amyloid fragment (25-35). Biochemistry 1994;33:1345-1350.
45. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA: A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91:3270-3274.
46. Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr: Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA-receptor and nitricoxide- synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 2001;76:1050-1056. (Pubitemid 32167378)
47. Albensi BC: The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Curr Pharm Des 2007;13:3185-3194.
48. Colmers WF, Bleakman D: Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci 1994;17:373-379. (Pubitemid 24256075)
49. Greber S, Schwarzer C, Sperk G: Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br J Pharmacol 1994;113:737-740. (Pubitemid 24326809)
50. Qian J, Colmers WF, Saggau P: Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. J Neurosci 1997;17:8169-8177. (Pubitemid 27461041)
51. Silva AP, Carvalho AP, Carvalho CM, Malva JO: Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus. J Neurochem 2001;79:286-296. (Pubitemid 32988944)
52. Silva AP, Carvalho AP, Carvalho CM, Malva JO: Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology 2003;44:282-292. (Pubitemid 36297036)
53. Smiałowska M, Domin H, Zieba B, Koźniewska E, Michalik R, Piotrowski P, Kajta M: Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 2009:235-249.
54. Xapelli S, Silva AP, Ferreira R, Malva JO: Neuropeptide Y can rescue neurons from cell death following the application of an excitotoxic insult with kainate in rat organotypic hippocampal slice cultures. Peptides 2007;28:288-294. (Pubitemid 46176273)
55. Vezzani A, Sperk G, Colmers WF, Neuropeptide Y: emerging evidence for a functional role in seizure modulation.Trends Neurosci 1999;22:25-30.
56. Sperk G, Hamilton T, Colmers WF: Neuropeptide Y in the dentate gyrus. Prog Brain Res 2007;163:285-297. (Pubitemid 47321441)
57. McQuiston AR, Petrozzino JJ, Connor JA, Colmers WF: Neuropeptide Y1 receptors inhibit N-type calcium currents and reduce transient calcium increases in rat dentate granule cells. J Neurosci 1996;16:1422-1429. (Pubitemid 26145922)
58. Kofler N, Kirchmair E, Schwarzer C, Sperk G: Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats. Neurosci Lett 1997;230:129-132. (Pubitemid 27312400)
59. Garzon DJ, Fahnestock M: Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 2007;27:2628-2635. (Pubitemid 46393608)
60. Liu H, Liu Z, Xu X, Yang X, Wang H, Li Z: Nerve growth factor regulates galanin and neuropeptide Y expression in primary cultured superior cervical ganglion neurons. Pharmazie 2010;65:219-223.
61. Wirth MJ, Patz S, Wahle P: Transcellular induction of neuropeptide Y expression by NT4 and BDNF. Proc Natl Acad Sci USA 2005;102:3064-3069. (Pubitemid 40299916)
62. Xapelli S, Bernardino L, Ferreira R, Grade S, Silva AP, Salgado JR, Cavadas C, Grouzmann E, Poulsen FR, Jakobsen B, Oliveira CR, Zimmer J, Malva JO: Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur J Neurosci 2008;27:2089-2102. (Pubitemid 351521490)
63. Kastin AJ, Akerstrom V: Nonsaturable entry of neuropeptide Y into brain. Am J Physiol 1999;276:E479-E482. (Pubitemid 29157402)
64. Kastin AJ, Pan W: Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides. Curr Pharm Des 2008;14:1615-1619. (Pubitemid 352002989)